Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 18/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 18/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 18/20 | 1.00 |
| ▸ | PRKCA | P17252 | 17/20 | 1.00 |
| ▸ | PRKCB | P05771 | 16/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 15/20 | 1.00 |
| ▸ | JAK3 | P52333 | 3/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647944 | 1.00 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL2500835 | 0.89 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29364923 | 0.89 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29526075 | 0.89 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL1992057 | 0.86 | PRKCH (0.76) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL1997849 | 0.85 | PRKCH (0.74) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL3846239 | 0.85 | PRKCH (0.93) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29412439 | 0.85 | PRKCH (0.93) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL31647812 | 0.80 | PRKCH (0.69) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL31647815 | 0.78 | PRKCH (0.67) | PRKCHPRKCQPRKCDPRKCAPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446043-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | claimed |
| US-20150306101-A1 | Pharmaceutical Combinations | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2015-10-29 | — | — | US | claimed |
| US-8748428-B2 | Use of a PKC inhibitor | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | claimed |
| EP-2552428-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| WO-2011120911-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | claimed |
| US-20110245256-A1 | USE OF A PKC INHIBITOR | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | claimed |
| US-20090131450-A1 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS | WAGNER JURGEN | 2009-05-21 | — | — | US | claimed |
| EP-2056831-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024734-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| EP-1855667-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE | Novartis AG (CH) | 2007-11-21 | — | — | EP | claimed |
| WO-2006092255-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE | NOVARTIS AG (CH) | 2006-09-08 | — | — | WO | claimed |
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018175302-A1 | POLYMER CONJUGATES TARGETING C-SRC WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2011120911-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | disclosed |
| EP-2004178-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-1911838-A1 | Crystalline forms of PKC alpha kinase, methods of making such crystals, and uses thereof | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008037688-A2 | CRYSTALLINE FORMS OF PKC ALPHA KINASE, METHODS OF MAKING SUCH CRYSTALS, AND USES THEREOF | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007107318-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245256-A1 | USE OF A PKC INHIBITOR | CD79B, PRKCB, BCL9 | PRKCH 9/4885PRKCQ 12/4885PRKCD 15/4885 |
| US-20150306101-A1 | Pharmaceutical Combinations | MAP2K1, PRKACA, MAP2K2 | PRKCH 5/4885PRKCQ 26/4885PRKCD 53/4885 |
| US-20090131450-A1 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS | PRKCH, PRKCA, PRKCB | PRKCH 1/4885PRKCQ 8/4885PRKCD 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.